Surf Wiki
Save to docs
general/acetylcholinesterase-inhibitors

From Surf Wiki (app.surf) — the open knowledge base

Ladostigil

Chemical compound

Chemical compound

| elimination_half-life =

Ladostigil (developmental code name TV-3326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders like Alzheimer's disease, Lewy body disease, and Parkinson's disease. It was developed from structural modification of rasagiline.

The drug acts as a reversible acetylcholinesterase and butyrylcholinesterase inhibitor, and an irreversible monoamine oxidase B inhibitor, and combines the mechanisms of action of older drugs like rivastigmine and rasagiline into a single molecule. In addition to its neuroprotective properties, ladostigil enhances the expression of neurotrophic factors like GDNF and BDNF, and may be capable of reversing some of the damage seen in neurodegenerative diseases via the induction of neurogenesis. Ladostigil also has antidepressant-like effects in animals, and may be useful for treating comorbid depression and anxiety often seen in such diseases as well.

There have been no new updates on the pharmaceutical development of ladostigil since 2019. At this time, it was in phase 2 clinical trials for Alzheimer's disease.

References

References

  1. (3 August 2022). "Ladostigil - Avraham Pharmaceuticals".
  2. (2000). "Advances in Research on Neurodegeneration". Journal of Neural Transmission. Supplementum.
  3. (August 2005). "Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease". Journal of Clinical Pharmacology.
  4. (January 2009). "Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs". Neurotherapeutics.
  5. (2006). "Parkinson's Disease and Related Disorders". Journal of Neural Transmission. Supplementum.
  6. (December 2007). "Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy". Annals of the New York Academy of Sciences.
  7. (March 2002). "Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression". Psychopharmacology.
  8. (June 2003). "A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease". Progress in Neuro-psychopharmacology & Biological Psychiatry.
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

acetylcholinesterase-inhibitors propargyl-compounds 1-aminoindanes carbamates monoamine-oxidase-inhibitors
Want to explore this topic further?

Ask Mako anything about Ladostigil — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report